Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Dr Lal PathLabs eyeing...

    Dr Lal PathLabs eyeing 18 per cent growth in FY17

    Written by savita thakur thakur Published On 2016-06-27T13:23:47+05:30  |  Updated On 27 Jun 2016 1:23 PM IST
    Dr Lal PathLabs eyeing 18 per cent growth in FY17

    New Delhi : Diagnostic services provider Dr Lal PathLabs is looking at around 18 per cent revenue growth this fiscal year as it undertakes initiatives to expand number of tests offered and its network across India.


    The company had posted a revenue of Rs 791.3 crore for the fiscal year 2015-16.


    "We are aiming for around 18 per cent growth in the current fiscal. We have been growing at that rate and will like to keep the momentum," Dr Lal PathLabs CEO Om Manchanda said.


    Elaborating on how the company planned to achieve the target, he said, "we would be adding 15 labs and around 200 collection centres, which are mainly franchise outlets during the fiscal year. The investment we will be making is between Rs 35-40 crore."


    The company will at the same time focus on providing better services,introducing new tests. It currently conducts nearly 2,000 tests, he added.


    When asked how the company planned to fund the expansion, Manchanda said, "it will be through internal accruals. We have sufficient funds."


    While deepening its presence in the North Indian market where it already has a strong presence, the company is also looking to scale up in other parts of the country as well.


    "Banking on our leadership in northern India, we are assertively moving into other potentially good geographies, the first of which will be East and Central India," he added.


    The company also plans to expand in to South and West India.


    "In south and west we have selected two cities Bengaluru and Pune. In these cities we will develop critical mass and then expand," Manchanda said.


    Dr LalPath Labs has 172 clinical labs and one central laboratory, over 1,500 collection centres and 4,967 pick-up points.


    Dr Lal PathLabsFY17growthInvestmentOm Manchanda
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok